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characteristics of the orphan drugs (OD) with the non-Orphan
drugs approved by the FDA in the period 1983–2007.
METHODS: All new chemical entities (NCE) approved by the
FDA in the study period were included in the study. Data derived
from the FDA’s Orange Book (OB). Differences between group
means were assessed using the t-test. Differences in proportions
were evaluated using chi-square and Fisher’s exact test.
RESULTS: Between January 4, 1983 and October 3, 2007 the
FDA granted 1749 OD designations and 315 OD approvals for
marketing. NCEs accounted for 17.7% of OD designations and
53.7% of OD approvals. The FDA approved 635 NCEs in the
study period, out of which 17.5% had OD status at the ﬁrst
NDA approval. Sponsors of ODs were more likely (p < 0.001) to
be US companies as compared to non-US companies (64.0% vs.
54.4%) and to have one NCE approval as compared to multiple
NCE during the study period (43.2% vs. 17.6%). ODs were less
likely (p < 0.001) to have at least one patent listed in the OB in
comparison with non-ODs (62.2% vs. 82.8%). ODs had less
patents listed in the OB than non-ODs (mean 1.7 vs. 2.3)
(p < 0.005). Exclusivity period was longer than the patent period
for 41.4% of the ODs and 21.4% of the non-ODs that had
patents listed in the OB (p < 0.001). ODs had less generic com-
petition than non-ODs (18.0% vs. 29.6%) (p < 0.05). CON-
CLUSION: US companies and companies with only one NCE
approval were more likely to use the Orphan drug regulatory
system. Orphan drugs have less number of patents, more exclu-
sivity protection and less generic competition than non-orphan
drugs.
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OBJECTIVE: To compare health care utilization changes
between Medicare beneﬁciaries with two prescription drug
beneﬁt structures who did and did not reach their respective Part
D drug beneﬁt spend threshold in 2006. METHODS: A retro-
spective analysis of a cohort of 28,392 Medicare Advantage
beneﬁciaries continuously enrolled into two distinct drug beneﬁt
structures for the year prior to and after implementation of the
Medicare Part D beneﬁt. The ﬁrst beneﬁt group (Silver) had the
Part D standard drug beneﬁt threshold ($2250) while the second
(Gold) had an enhanced beneﬁt with a higher threshold ($3500).
Poisson, zero-inﬂated Poisson, and negative binomial modeling
were used to compare post-implementation utilization rates with
adjustment for pre-period utilization, demographics and morbid-
ity burden. RESULTS: A total of 1237 (6%) Silver and 526 (8%)
Gold beneﬁciaries reached their threshold. Among both groups,
beneﬁciaries who reached their threshold had greater morbidity
burden and higher rates of pre-period inpatient admissions and
medical ofﬁce and ED visits (all p < 0.001). Among beneﬁciaries
who reached their threshold, there was no change in inpatient
and ED (both p > 0.05) but an increase in medical ofﬁce visit
(p < 0.001) utilization rates in comparable 6-month periods
before and after reaching their threshold. Sub-analyses indicated
that beneﬁciaries with the highest morbidity burden experienced
higher utilization rates (all p < 0.05), but there were no differ-
ences between groups (all p > 0.05). Beneﬁciaries in both groups
who did reach their threshold had higher post-period utilization
rates (all p < 0.001) regardless of age and morbidity burden and
were more likely to die (p < 0.001) compared to beneﬁciaries
who did not reach their threshold. CONCLUSION: Although
many Medicare beneﬁciaries navigate their drug spend threshold
without experiencing increased health care utilization, those with
high morbidity burdens are at risk of increased health care uti-
lization and the potential for adverse outcomes. It is imperative
that strategies be developed that help safeguard vulnerable Medi-
care beneﬁciaries.
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OBJECTIVE: Investigate the variation in Medicare claim-paying
agents (carriers) reimbursement to physicians for chemotherapy
and evaluate the inﬂuence of Medicare carrier chemotherapy
reimbursement on G-CSF choice. G-CSF is an expensive drug to
manage febrile neutropenia with uncertain beneﬁts. METHODS:
Using the national SEER-Medicare linked database, we studied
patients 66 years or older diagnosed as NHL in one of the 13
SEER registry areas from 1994–2002. We grouped counties
within SEER based on Medicare carrier coverage. We then esti-
mated a regression model describing total physician reimburse-
ment during the ﬁrst cycle of chemotherapy (total Medicare part
B and Medicare outpatient reimbursements within 21 days of the
chemotherapy start date) to construct average Medicare chemo-
therapy physician reimbursement measures for these county
groups. Logistic regression was performed to assess the inﬂuence
of Medicare carrier chemotherapy reimbursement on the use of
G-CSF. RESULTS: F test from the regression model showed
statistically signiﬁcant variation in the reimbursement for ﬁrst
cycle chemotherapy by counties grouped by carrier coverage (P
value = 0.0017). We found that Medicare carrier-related chemo-
therapy reimbursement had a non-linear relationship with the
use of G-CSF. Both linear and squared reimbursement terms were
statistically signiﬁcant. An increase in chemotherapy reimburse-
ment from initially low reimbursement levels resulted in a
decrease in the use of G-CSF and this relationship went away at
higher chemotherapy reimbursement levels. CONCLUSION:
Medicare physician reimbursement for chemotherapy varies
across Medicare carriers and this variation affects the decision of
physicians to prescribe G-CSF. At low chemotherapy reimburse-
ment levels, increases in chemotherapy reimbursements decreases
G-CSF prescribing. Physicians appear to compensate for lower
reimbursements by increasing the intensity of their services.
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OBJECTIVE: Little is known about how Medicare Part D utili-
zation varies based on subjects’ pre-Part D prescription coverage
and comorbidities. METHODS: We examined claims from a
national pharmacy chain from 2005 and 2006 accounting for
approximately 15% of the U.S. prescription drug market. We
focused on beneﬁciaries ages 66–79 as of January 1, 2006. We
focused on the association between pre-Part D insurance gener-
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